Tarsus Pharmaceuticals, Inc. Financials

Market Capitalization $1.78 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-10.56
Forward PE	-21.56
Price to Sales TTM	$13.74
Price to Book MRQ	$7.49
Enterprise to Revenue	11.84
Enterprise to EBITDA	-11.00

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	-103.64%
Operating Margin	-52.29%
Return on Assets TTM	-27.26%
Return on Equity TTM	-59.56%

Income Statement

Revenue TTM	$129,621,000
Revenue per Share TTM	$3.57
Quarterly Revenue Growth	2471.80%
Gross Profit TTM	$107,200,000
EBITDA	$-139,458,000
Net Income to Common TTM	$-134,343,008
Diluted EPS TTM	$-3.75
Quarterly Earnings Growth YoY	2471.78%

Balance Sheet

Total Cash MRQ	$316,952,000
Total Cash per Share MRQ	$8.29
Total Debt MRQ	$
Total Debt to Equity MRQ	30.20
Current Ratio MRQ	5.42
Book Value per Share MRQ	$6.22

Cash Flow

Operating Cash Flow TTM	$-100,180,000
Levered Free Cash Flow TTM	$-71,101,504

TARS Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	38,226,900
Float Shares	28,973,719
Avg 10 Volume	910,699
Avg 30 Volume	None
Shares Short	7,328,028
Short Ratio	14.07
Short % of Shares	19.87%
% Held by Insiders	8.73%
% Held by Institutions	120.74%

Stock Price Summary

Beta
Fifty Two Week Low	$20.08
Fifty Two Week High	$57.14
Fifty Two Week Change	42.64%
Day 50 MA	$50.42
Day 200 MA	$36.46

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date